Comparison of the expression of LncRNAs BACE-AS1, NEAT1, and GAS5 in the AD patients and HC groups all showed a significant increase in expression and a total sensitivity and specificity of 74% and 88% based on the ROC, and it was found that lncRNAs have a high level of discriminatory power when used as diagnostic biomarkers for AD [110]. This evidence concerns the gene BACE1 and Alzheimer disease.